$JNJ (Johnson & Johnson)

$JNJ {{ '2016-07-26T16:15:18+0000' | timeago}} • Announcement

$JNJ's unit Janssen Research & Development said the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for use in combination with standard of care regimens for patients with multiple myeloma. Multiple myeloma is incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in bone marrow.

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$JNJ {{ '2017-12-21T18:10:50+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said the FDA has granted Priority Review designation for the New Drug Application (NDA) for apalutamide as treatment for non-metastatic castration-resistant prostate cancer (CRPC). This is the first agent submitted for approval to treat earlier stage castration-resistant prostate cancer at high risk for metastasis.

$MDT {{ '2017-11-22T20:29:59+0000' | timeago}} • Webcast

In Oct., Animas announced to cease the manufacture and sale of its insulin pumps and partnered with $MDT to offer its customers the opportunity to transfer to a new device.With $JNJ exiting the insulin pump market in the US and Canada, $MDT now has access to the 90,000 patients who use Animas insulin pumps.

$JNJ {{ '2017-10-27T11:25:43+0000' | timeago}} • Announcement

Janssen Pharmaceutical, a $JNJ company, said the Phase 3 AMBER study achieved its primary endpoint and showed that its investigational regimen containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg showed positive results in previously untreated HIV-1 positive adults.

$JNJ {{ '2017-10-19T14:38:55+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 4Q17 of $0.84 per share on its common stock. The dividend is payable on Dec 12, 2017 to shareholders as on Nov 28, 2017.

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$JNJ {{ '2017-10-17T19:18:23+0000' | timeago}} • Webcast

$JNJ said sale of its blockbuster drug Remicade, used in the treatment of rheumatoid-arthritis declined 7.6% to $1.6Bil in 3Q17, hurt by competition from cheaper alternatives called biosimilars. The pharma giant said it has reduced Remicade's price, in view of tight competition in the market.

$JNJ {{ '2017-10-17T18:41:27+0000' | timeago}} • Webcast

Speaking on the effect of Hurricane Maria that hit Puerto Rico last month, $JNJ said all six of its plants on the island are making and shipping drugs using energy from generators. Though the company said intermittent shortage of drugs cannot be ruled out, it added that it does not see any material impact of the hurricane on future results.

$JNJ {{ '2017-10-17T13:40:49+0000' | timeago}} • Webcast

Only months after promising investors a slew of new blockbuster drugs, $JNJ said it has decided to discontinue clinical trials for two of its drugs. Sirukumab, for the treatment of rheumatoid arthritis, and talacotuzumab, for the treatment of myeloid leukemia, are the drugs that have been discontinued.

$JNJ {{ '2017-10-17T12:09:28+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q3 2017 Highlights

$JNJ {{ '2017-10-17T11:47:16+0000' | timeago}} • Announcement

$JNJ raised its sales and adjusted earnings guidance for FY17. The New Brunswick, NJ-based healthcare giant now expects sales for the period to be in the range of $76.1 - 76.5Bil, verses the prior guidance of $75.8 - 76.1Bil. Adjusted earnings is anticipated to be $7.25 - $7.30 per share, compared to the prior guidance of $7.12 - $7.22 per share.

$JNJ {{ '2017-10-17T11:36:50+0000' | timeago}} • Announcement

Kicking off the earnings season in healthcare sector, $JNJ reported 10.3% growth in its sales to $19.7Bil in 3Q17. Adjusted earnings also rose double digits to $5.2Bil, or $1.90 per share, driven by strong growth in Pharma unit, as well as Actelion acquisition. On a GAAP basis, earnings fell 12% to $3.8Bil, or $1.37 per share.

$JNJ {{ '2017-10-16T14:43:30+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech Inc. has received FDA approval for an expanded indication for STELARA for the treatment of adolescents with plaque psoriasis.

$JNJ {{ '2017-10-05T13:58:49+0000' | timeago}} • Announcement

Animas Corp., a $JNJ Diabetes Care Companies, plans to discontinue the manufacturing and sale of Animas Vibe and OneTouch Ping insulin pumps, close operations and exit the insulin pump business. Animas has selected $MDT as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers.

$JNJ {{ '2017-10-02T21:24:15+0000' | timeago}} • Announcement

$JNJ completed divestiture of its Codman Neurosurgery business to $IART for about $1.045Bil. The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neuro intensive care and cranial surgery, and generated net revenues of about $371.5MM in 2016.

$JNJ {{ '2017-09-26T16:07:37+0000' | timeago}} • Announcement

Janssen-Cilag International NV, a $JNJ company, said the European Commission has approved the use of Symtuza, a once-daily darunavir-based single-tablet regimen, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg.

$JNJ {{ '2017-09-22T21:34:55+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech, Inc. received a complete response letter from the US FDA for the Biologics License Application (BLA) seeking approval of sirukumab for the treatment of moderately to severely active rheumatoid arthritis. The letter states that additional clinical data are needed to further evaluate the safety of sirukumab.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$JNJ {{ '2017-09-06T18:27:40+0000' | timeago}} • Announcement

Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of $JNJ, received FDA approval for a new 32 mg tablet for oral suspension for TRACLEER for use in pediatric patients aged three years and older, suffering from high blood pressure in the arteries of the lungs. The medication will be available from 4Q17.

$JNJ {{ '2017-08-28T15:56:47+0000' | timeago}} • Announcement

$JNJ said results from a Phase 3 study found that the XARELTO plus aspirin 100 mg once daily significantly reduced the risk of major cardiovascular (CV) events including CV death, heart attack or stroke by 24% in patients with stable coronary and/or peripheral artery disease, compared to aspirin alone. The study was conducted on 27,395 patients.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
DRRX (DURECT Corporation)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
CYTK (Cytokinetics, Incorporated)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
VCEL (Vericel Corporation)
Wednesday, August 9 2017 - 12:00pm

AlphaGraphics you may like